The Library
NEAT : national epirubicin adjuvant trial - toxicity, delivered dose intensity and quality of life
Tools
Tools
Tools
Behalf NEAT Investigators (Including: Earl, Helena M., Hiller, Louise, Dunn, Janet A., Bathers, S., Harvey, P., Stanley, A., Grieve, R. J., Agrawal, R. K., Fernando, I. N., Brunt, A. M., McAdam, K., O'Reilly, S., Rea, D. W., Spooner, David A. and Poole, Christopher). (2008) NEAT : national epirubicin adjuvant trial - toxicity, delivered dose intensity and quality of life. British Journal of Cancer, Vol.99 (No.8). pp. 1226-1231. doi:10.1038/sj.bjc.6604674
Research output not available from this repository, contact author.
Official URL: http://dx.doi.org/10.1038/sj.bjc.6604674
Abstract
The NEAT trial reported considerable benefit for ECMF (epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil) of 28% for relapse-free survival (RFS) and 30% for overall survival (OS), when compared with classical CMF in early breast cancer. To assess tolerability, toxicity, dose intensity and quality of life (QoL) analyses were undertaken. All 2021 eligible patients had common toxicity criteria (CTC), delivered chemotherapy and supportive treatments details and long-term morbidities recorded. The QoL substudy used multiple validated measures. ECMF produced low CTC scores, although higher than CMF for nausea, vomiting, alopecia, constipation, stomatitis (P = 0.001), infection (P = 0.001) and fatigue (P=0.03). Supportive treatments required, however, were similar across randomised treatments. On-treatment deaths were more common with CMF (13) than ECMF(5). Optimal course-delivered dose intensity (CDDI >= 85%) was received more often by ECMF patients (83 vs 76%: P = 0.0002), and was associated with better RFS (P = 0.0006). QoL over 2 years was equivalent across treatments, despite minimally worse side effects for ECMF during treatment. ECMF benefit spanned all levels of toxicity, CDDI and QoL. There are no reported acute myeloid leukaemias or cardiac dysfunctions. ECMF is tolerable, deliverable, and significantly more effective than CMF, with no serious longterm toxicity or QoL detriment.
| Item Type: | Journal Article | ||||
|---|---|---|---|---|---|
| Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) | ||||
| Divisions: | Faculty of Medicine > Warwick Medical School > Health Sciences Faculty of Medicine > Warwick Medical School |
||||
| Library of Congress Subject Headings (LCSH): | Breast -- Cancer -- Treatment -- Research, Cancer -- Adjuvant treatment -- Research | ||||
| Journal or Publication Title: | British Journal of Cancer | ||||
| Publisher: | Nature Publishing Group | ||||
| ISSN: | 0007-0920 | ||||
| Official Date: | 14 October 2008 | ||||
| Dates: |
|
||||
| Volume: | Vol.99 | ||||
| Number: | No.8 | ||||
| Number of Pages: | 6 | ||||
| Page Range: | pp. 1226-1231 | ||||
| DOI: | 10.1038/sj.bjc.6604674 | ||||
| Status: | Peer Reviewed | ||||
| Publication Status: | Published | ||||
| Access rights to Published version: | Restricted or Subscription Access | ||||
| Funder: | Cancer Research Campaign (Great Britain) (CRC), Pharmacia Corp. |
Data sourced from Thomson Reuters' Web of Knowledge
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
